Scientists have reported a major breakthrough in our understanding of inflammatory bowel disorder. It could lead to more effective treatments for conditions like Crohn's disease, a new study found.

Although several treatment options exist in the management of Crohn's disease, a patient-centered approach is integral amid ...

A three-day National Inflammatory Bowel Disease (IBD) Conference and the second roundtable meeting of the BRICS IBD Consortium, being organised by the Vizag Gut Club Association in collaboration with ...

Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025.

A lthough some health conditions are spoken about with more nuance and understanding than in the past, inflammatory bowel ...

Researchers sought to determine the prevalence, characteristics, management, and outcomes of difficult-to-treat IBD.

Mayo Clinic researchers are aiming to create a bioelectric device that carries genetically engineered cells to generate ...

Shattuck Labs Inc. has announced a strategic shift to focus on SL-325, a death receptor 3 (DR3) antagonist antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory ...

Mayo Clinic is the prime site for an ARPA-H award to develop an implantable device that acts as a living pharmacy, triggering a "cell factory" in the body to treat inflammatory disease. ARPA-H, short ...

An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...

Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of ...

A unique glycosylation signature on circulating antibodies is detectable in blood up to 6 years before a diagnosis of Crohn's ...